

Table S2 Baseline and historical peripheral and extra-articular manifestations of axial spondyloarthritis: COAST-V and COAST-W (ITT population)

	COAST-V (bDMARD-naïve)				COAST-W (TNFi-experienced)		
	PBO (N=87)	ADA (N=90)	IXE Q4W (N=81)	IXE Q2W (N=83)	PBO (N=104)	IXE Q4W (N=114)	IXE Q2W (N=98)
Arthritis							
Current	24 (27.9)	21 (23.3)	26 (32.1)	20 (24.1)	38 (36.5)	39 (34.2)	37 (37.8)
Historical only	5 (5.8)	5 (5.6)	3 (3.7)	4 (4.8)	12 (11.5)	10 (8.8)	11 (11.2)
Anterior uveitis							
Current	2 (2.3)	5 (5.6)	1 (1.2)	4 (4.8)	2 (1.9)	4 (3.5)	1 (1.0)
Historical only	12 (14.0)	14 (15.6)	16 (19.8)	17 (20.5)	25 (24.0)	17 (14.9)	25 (25.5)
Psoriasis							
Current	8 (9.3)	5 (5.6)	4 (4.9)	3 (3.6)	13 (12.5)	13 (11.4)	8 (8.2)
Historical only	0	1 (1.1)	0	0	2 (1.9)	2 (1.8)	1 (1.0)
Crohn's disease or ulcerative colitis							
Current	1 (1.2)	1 (1.1)	0	1 (1.2)	3 (2.9)	2 (1.8)	0
Historical only	1 (1.2)	0	1 (1.2)	1 (1.2)	0	0	3 (3.1)
Dactylitis							
Current	2 (2.3)	0	1 (1.2)	3 (3.6)	6 (5.8)	3 (2.6)	3 (3.1)
Historical only	0	2 (2.2)	0	0	0	4 (3.5)	1 (1.0)
Enthesitis							
Current	21 (24.4)	18 (20.0)	21 (25.9)	15 (18.1)	33 (31.7)	37 (32.5)	30 (30.6)
Historical only	5 (5.8)	4 (4.4)	3 (3.7)	4 (4.8)	8 (7.7)	4 (3.5)	10 (10.2)

Data are n (%) and are presented for patients with non-missing values.

ADA, adalimumab; bDMARD, biological disease-modifying antirheumatic drug; ITT, intent-to-treat; IXE Q4W, ixekizumab 80 mg every 4 weeks; IXE Q2W, ixekizumab 80 mg every 2 weeks; PBO, placebo; TNFi, tumour necrosis factor inhibitor.